Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleSpecial Section on Natural Products: Experimental Approaches to Elucidate Disposition Mechanisms and Predict Pharmacokinetic Drug Interactions — Minireview

Natural Products as Modulators of CES1 Activity

Yuli Qian and John S. Markowitz
Drug Metabolism and Disposition October 2020, 48 (10) 993-1007; DOI: https://doi.org/10.1124/dmd.120.000065
Yuli Qian
Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, Florida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yuli Qian
John S. Markowitz
Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, Florida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Carboxylesterase (CES) 1 is the predominant esterase expressed in the human liver and is capable of catalyzing the hydrolysis of a wide range of therapeutic agents, toxins, and endogenous compounds. Accumulating studies have demonstrated associations between the expression and activity of CES1 and the pharmacokinetics and/or pharmacodynamics of CES1 substrate medications (e.g., methylphenidate, clopidogrel, oseltamivir). Therefore, any perturbation of CES1 by coingested xenobiotics could potentially compromise treatment. Natural products are known to alter drug disposition by modulating cytochrome P450 and UDP-glucuronosyltransferase enzymes, but this issue is less thoroughly explored with CES1. We report the results of a systematic literature search and discuss natural products as potential modulators of CES1 activity. The majority of research reports reviewed were in vitro investigations that require further confirmation through clinical study. Cannabis products (Δ9-tetrahydrocannabinol, cannabidiol, cannabinol); supplements from various plant sources containing naringenin, quercetin, luteolin, oleanolic acid, and asiatic acid; and certain traditional medicines (danshen and zhizhuwan) appear to pose the highest inhibition potential. In addition, ursolic acid, gambogic acid, and glycyrrhetic acid, if delivered intravenously, may attain high enough systemic concentrations to significantly inhibit CES1. The provision of a translational interpretation of in vitro assessments of natural product actions and interactions is limited by the dearth of basic pharmacokinetic data of the natural compounds exhibiting potent in vitro influences on CES1 activity. This is a major impediment to assigning even potential clinical significance. The modulatory effects on CES1 expression after chronic exposure to natural products warrants further investigation.

SIGNIFICANCE STATEMENT Modulation of CES1 activity by natural products may alter the course of treatment and clinical outcome. In this review, we have summarized the natural products that can potentially interact with CES1 substrate medications. We have also noted the limitations of existing reports and outlined challenges and future directions in this field.

Introduction

The potential for pharmacokinetic interactions between natural products and conventional medications and the risks of associated therapeutic failure or toxicity continues to be a clinical concern (Johnson et al., 2018). To date, the vast majority of natural product–drug interaction (NPDI) research has focused on cytochrome P450 (P450) enzymes and UDP-glucuronosyltransferases (UGTs). However, there is accumulating literature implicating carboxylesterase (CES) 1 in NPDI. This review focuses on those reports.

Carboxylesterases have been isolated from diverse sources, including bacteria, fungi, algae, plants, animals, and humans. In humans, CES enzymes are classified into five subfamilies: CES1, CES2, CES3, CES4A, and CES5A (Holmes et al., 2010). CES1 and CES2 are the two primary forms that appear relevant to drug metabolism. Distinct differences between CES1 and CES2 have been identified relative to localization, substrate specificity, and gene regulation. CES1 is far more abundant in the liver than CES2, whereas CES2 predominates in the intestine (Hosokawa and Satoh, 1988; Imai et al., 2006). CES1 and CES2 are among the most abundant drug-metabolizing enzymes (DMEs) in the liver, constituting 42.9% and 1.4% of protein expressions of major phase I and phase II DMEs (i.e., P450s, UGTs, and CESs), respectively, in human liver microsomes (Fig. 1) (He et al., 2019). In the present review we have focused on CES1, which is involved in the biotransformation of the majority of therapeutic agents that are known CES substrates.

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Relative abundance of major DMEs in human liver microsome. The percentage values represent the relative quantities of individual enzymes in the major DMEs (i.e., P450s, UGTs, CESs) by molar unit. The molar values are derived from He et al. (2019).

CES1 catalyzes the hydrolysis of various endogenous compounds (e.g., triacylglycerols) and xenobiotics containing structures of esters, amides, thioesters, and carbamates. In order of abundance, CES1 is primarily expressed in the liver, gallbladder, and lung (Hatfield et al., 2011; Di, 2019), and it is the predominant hydrolase in the liver, where it has been estimated to account for 80%–95% of its hydrolytic activity (Imai et al., 2006; Ross and Crow, 2007). Therefore, CES1 can be considered a major phase I DME and plays an essential role in the biotransformation of medications in both liver and lung. Indeed, drugs from almost all therapeutic classes (Table 1) have been identified as CES1 substrates (Her and Zhu, 2020). Depending on the structure and design of CES1 substrate medications, hydrolysis by CES1 either transforms a nonactive esterified prodrug (e.g., oseltamivir) into its active form (prodrug substrates identified in Table 1) or inactivates the pharmacologically active moieties (e.g., methylphenidate) by converting them into their inactive acid form. Among the molecular entities approved by the US Food and Drug Administration in the last decade, approximately 10% had “esterase” listed as their primary metabolic pathway (Drugs@FDA: FDA-Approved Drugs). When we examined the approval documents of these described esterase substrates, the majority did not specify the individual esterase, presumably because of the assumption of insignificant influence from a single esterase. However, an increasing number of research reports have documented that specific genetic mutations of the CES1 gene result in impairment in CES1 activity, influencing both the pharmacokinetics and pharmacodynamics of its substrates. For example, a healthy volunteer participating in a pharmacokinetic drug interaction study of racemic (dl)-methylphenidate and ethanol was discovered to be carrying two previously undocumented CES1 mutations, p.Gly143Glu (G143E) and p.Asp260fs, resulting in profound alterations in the metabolism and disposition of methylphenidate (Zhu et al., 2008). Notably, the Cmax of total methylphenidate was ∼7-fold higher in this subject than the remaining participants. In other studies, individuals carrying the G143E mutation, a loss-of-function variant, were found to have higher exposure to the active metabolite of the antiplatelet drug clopidogrel combined with an enhanced pharmacodynamic (i.e., antiplatelet) effect (Lewis et al., 2013; Tarkiainen et al., 2015). In the Lewis study, single determination of the active metabolite concentration increased by 59% in the G143E carriers, along with a 24% in the reduction of platelet aggregation (Lewis et al., 2013). In the Tarkiainen study, the area under the concentration-time curve to infinite time (AUC0-inf) and Cmax of the active metabolite were 67% and 63% higher, respectively, in subjects carrying the G143E variant. Consistently, the average platelet inhibition was 31% higher in the G143E subjects (Tarkiainen et al., 2015). Additionally, the requisite metabolic activation of the CES1 substrate and prodrug oseltamivir has been shown to be markedly affected by the G143E variant. This has been demonstrated in vitro using cell lines stably transfected with the CES1 variant (Zhu and Markowitz, 2009) as well as in single-dose clinical studies in healthy volunteer G143E carriers and noncarriers (Tarkiainen et al., 2012), suggesting that the therapeutic activity of this anti-influenza agent may be compromised in carriers. Indeed, one G143E homozygous subject had an AUC0–inf of the parent drug oseltamivir that was ∼360% greater than that of noncarrier study peers. This striking difference highlights the potential therapeutic consequences of compromised CES1 activity in individuals treated with CES1 substrate medications.

View this table:
  • View inline
  • View popup
TABLE 1

Substrates of CES1 as established by in vitro assay

Similarly, metabolic inhibition of CES1 by certain therapeutic agents or other substances including alcohol can lead to altered exposure to concomitantly administered CES1 substrates, such as methylphenidate and oseltamivir (Zhu et al., 2011; Patrick et al., 2013; Parker et al., 2015; Zhu et al., 2017). Thus, it is established that perturbations in CES1 activity can have clinical implications for patients treated with CES1 substrate medications.

Natural products broadly refers to the chemical compounds or preparations with a natural origin. These include foods, herbal or botanical medicines, and dietary supplements other than botanical products (e.g., vitamins). In many countries and cultures, notably China and India, herbs have been widely used and accepted in the practice of traditional medicine and carry a long and documented history of preparation and established pharmacopoeias for specific medical indications. These traditional medicines may be singular plant materials or extracts or complex mixtures of plant species. In the United States, the interest in and use of botanical supplements is far more recent, yet it has grown tremendously in the last two decades. Despite a required disclaimer of effectiveness for any medical indication on their labels, they are widely viewed as health-promoting by the United States lay public, and sales have been growing exponentially, reaching a total of $8.8 billion in the United States in 2018 (Gurley et al., 2018; Smith et al., 2019). However, botanical supplements require neither a rigorous development process, as is required for conventional medications, nor Food and Drug Administration scrutiny or approval prior to marketing. As a consequence, interactions between natural products and conventional medications are almost exclusively identified in the postmarketing period and take the form of adverse event case reports. Notable examples are grapefruit juice and Saint John’s wort, which were found to exert potent inhibitory and inductive effect on the P450s, respectively (Bailey et al., 1998; Moore et al., 2000; Markowitz et al., 2003; Hanley et al., 2011; Bailey et al., 2013). Moreover, adverse events associated with the use of natural products may not be suspected, recognized, or efficiently reported by patients or physicians (Cellini et al., 2013), and potential use of multiple botanical products or botanical mixtures—a common practice—further complicates the issue. It is therefore essential to perform assessments of the potential for widely used botanical formulations to participate in significant botanical-drug interactions (BDI).

To date, the overwhelming number of published reports and investigations of BDIs involve the phase I P450 system and the phase II UGT enzyme system. Botanical influences on drug transporter activity have also been an area of investigation. Historically, relatively little has been explored or reviewed regarding the potential role of esterases in BDIs. However, in recent years, there has been a substantial increase in the number of published reports on putative BDIs implicating CES1. In the present review, we examine both in vitro and in vivo studies, with the aim of summarizing the methodology of studies carried out, their key findings, and when possible, identifying those natural products that can potentially modulate CES1 activity in a clinically significant manner under achievable exposure scenarios.

Materials and Methods

Systematic literature searches were performed utilizing the MEDLINE and Embase databases. All pertinent studies, reviews, and case reports through February 2020 were retrieved. The search terms (“carboxylesterase 1” OR “CES1” OR “hCE1”) AND (“drug-drug interaction” OR “drug interaction” OR “herb-drug interaction” OR “botanical-drug interaction” OR “inhibitor” OR “inhibition” OR “inducer” OR “induction”) were incorporated. Articles were excluded if they were 1) not published in English; 2) not focused on the modification of CES1 activity by xenobiotics; and 3) not accessible in full text. Further refinement narrowed down studies to those involving natural products (n = 16). Additional search terms (“carboxylesterase”) AND (“drug-drug interaction” OR “drug interaction” OR “herb-drug interaction” OR “botanical-drug interaction”) and cross-referencing of published bibliographies was also applied, yielding eight more articles of interest. In the final selection of articles, papers that solely presented animal studies (n = 3) were excluded from this review, as animal models of drug interactions have limited translatability because of factors including interspecies differences in metabolism, the near-universal use of intraperitoneal dosing routes, and others. One report was also excluded because of the insufficient details provided, rendering a final total of 20 articles that were retrieved and reviewed. A flowchart of the systematic literature search was presented in Fig. 2.

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Flowchart of systematic literature searches utilizing the MEDLINE and Embase databases.

The prediction of potential clinical interaction is made based on considerations of both the in vitro inhibition potency and the achievable clinical exposure of identified inhibitors. Since the in vivo concentration of a given inhibitor at an active or modulatory site is generally not known, its estimate is typically based upon available pharmacokinetic values, such as unbound or free concentration of the compound in plasma, with the assumption that it is this concentration presented to hepatocytes, P450, or other enzymes or transporters (Markowitz et al., 2008). However, with botanical constituents, there is an overall dearth of human pharmacokinetic data, which limits the ability to provide reliable estimates. Within this review, we assessed available pharmacokinetic studies of those compounds in humans and retrieved the maximum blood/plasma/serum concentration (Cmax, [I]) values after their common routes of administration. The prediction was based on the ratio of Cmax ([I]) over the in vitro inhibition constant (Ki) or IC50. A ratio value ([I]/Ki or IC50) between 0.1 and 1 indicates moderate interaction risks (Bachmann and Lewis, 2005; Wienkers and Heath, 2005; Zhang et al., 2009), and a value higher than 1 is considered of high interaction risk (Bachmann and Lewis, 2005; Wienkers and Heath, 2005). We consider a clinically significant interaction possible when either of the two risk categories is expected. Inhibitors that failed to achieve more than 50% inhibition were excluded from the assessment. Notably, many flavonoids were present in human blood/plasma/serum as both free compounds and their conjugated metabolites. The parent compounds and metabolites were not differentiated in most of the research reports, depending on the employed bioanalytical approaches. In our assessment, we focused on the free compound concentrations whenever possible. The total concentrations were used if the free concentrations were not available, with the assumption of equal inhibitory potency among the free compounds and their conjugated metabolites.

Results

A total of 20 published reports were evaluated that involve assessment of approximately 36 herbal preparations or botanical extracts and more than 146 specific phytoconstituents. The majority of original research reports reviewed used one or more in vitro systems for data generation (n = 19). However, one healthy human subject study was also identified. The in vitro assessments are summarized in Table 2. Botanical formulations or constituents with CES1-modulating activity were summarized into their respective chemical groups. For each natural product, results of in vitro and clinical drug interaction studies and their clinical exposure are provided.

View this table:
  • View inline
  • View popup
TABLE 2

In vitro assessments of modulatory effects of natural products on CES1

Cannabinoids

Cannabinoids are found in the plant cannabis (Cannabis sativa L.), a widely abused substance globally and in the United States. The use of recreational cannabis in the United States is widespread and increased significantly in the last decade (https://www.samhsa.gov/data/report/2018-nsduh-detailed-tables). Additionally, in the United States, there are presently 33 states as well as the District of Columbia that permit the use of “medical cannabis” or “medical marijuana” for one or more medical indications. The allowable form of cannabis or specific constituents as well as dosing routes differ from state to state. Most all of the states permit the use of medical cannabis in the treatment of diseases such as cancer, epilepsy, and human immunodeficiency virus/AIDS and numerous other chronic conditions (Bridgeman and Abazia, 2017). Thus, the presence and use of concurrent conventional medications with cannabis is commonplace. The ability of cannabinoids to interact with a variety of DMEs has been documented both in vitro and clinically (Cox et al., 2019; Qian et al., 2019a).

In Vitro Studies.

The potential modulatory effects of three major cannabinoids on CES1 were assessed in a recombinant system by Qian et al. (2019b). All three cannabinoids [∆9-tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN)] exhibited potent in vitro inhibition, with Ki values of 0.541, 0.974, and 0.263 µM, respectively. The study further showed an enhanced extent of CES1 inhibition by combining three major cannabinoids in the in vitro system, suggesting a higher than expected interaction risk after certain administration routes of cannabis products (e.g., smoking and vaping). Consistently, THC, CBD, and CBN were found to exert in vitro inhibition on the hepatic hydrolysis of heroin, a potentially concomitantly used substance and partial substrate of CES1 (Qian et al., 2020).

Clinical Exposure.

The highest systemic exposure to THC appears to be achieved by recreational use (i.e., smoking) of cannabis cigarettes. In a study conducted by Huestis et al. (1992), a mean THC plasma Cmax of 162 ng/ml was observed in healthy males (n = 6) after smoking a cannabis cigarette containing 3.55% THC. This observation was similar to several other pharmacokinetic studies (Lindgren et al., 1981; Perez-Reyes et al., 1982). The naturally occurring CBD and CBN are much lower in content than THC in cannabis products (Mehmedic et al., 2010), which leads to minimal exposure to them in the human body (Schwope et al., 2011; Desrosiers et al., 2014; Newmeyer et al., 2016). CBD has been developed as an oral solution (Epidiolex) for treatment of two severe forms of epilepsy in children, with which a significantly higher exposure was achieved (Cmax = 732 ng/ml after the second 750 mg twice-daily dose) (Taylor et al., 2018). When administered orally as a dietary supplement, measurable CBD concentrations were present in the blood circulation (Atsmon et al., 2018; Knaub et al., 2019; Patrician et al., 2019; Hobbs et al., 2020). The highest reported CBD exposure through this route (Cmax = 77.6 ng/ml) was observed in healthy males (n = 12) after receiving 90 mg of CBD in a recently developed capsule formulation (Patrician et al., 2019). The highest documented CBN exposure was 11.6 ng/ml after smoking cannabis cigarettes (Newmeyer et al., 2016).

Flavonoids

Flavonoids are a large family of polyphenolic plant compounds. Existing as secondary plant metabolites, there are six major subclasses of flavonoids: anthocyanidins, flavan-3-ols, flavonols, flavanones, flavones, and isoflavones. Flavonoids are found abundantly in nature within fruits, vegetables, grains, bark, roots, flowers, and some beverages, such as tea and wine. It has been estimated that >9000 unique flavonoids exist in nature, and many are believed to convey beneficial health properties, including antioxidant, antioncogenic, procardiovascular, anti-inflammatory, and antimicrobial activities (Ververidis et al., 2007; Ferrer et al., 2008). Flavonoids usually occur as glycosides in nature, which are hydrolyzed and absorbed in intestine after ingestion. The absorbed flavonoids are usually conjugated rapidly and appear in the circulation both as the free aglycone and conjugated forms.

Although the most common dietary sources of flavonoids are fruits and vegetables, flavonoids can also be found in a wide variety of herbs used in traditional medicines and within specific dietary supplements.

In Vitro Studies.

The flavonoids in grapefruit (Citrus × paradisi) juice were investigated by Li et al. (2007) for their potential modulatory effects on esterases in human liver microsomes (HLM). Kaempferol, quercetin, morin, galangin, and naringenin inhibited the esterase activity, with IC50 values ranging from 30 to 81 µM. Similarly, Shimizu et al. (2014) showed that 68% and 81% of the hydrolytic activity of recombinant CES1 was inhibited by 100 µM kaempferol and quercetin, respectively. In addition, the inhibitory effects of quercetin (IC50 = 33.4 µM) and galangin (IC50 = 11.4 µM) on CES1 were confirmed in an HLM system by Wang et al. (2018b).

Fructus psoraleae (buguzhi), a widely used traditional Chinese medicine (TCM) prepared as the dried ripe fruit of Psoralea corylifolia L., is commonly used for treatment of a diverse group of conditions, including vitiligo, cardiovascular diseases, osteoporosis, and nephritis. Many compounds have been isolated from fructus psoraleae, including flavonoids, chalcones, coumarins, monoterpenoids, and others (Zhou et al., 2019). In one investigation, the major flavonoids from fructus psoraleae (neobavaisoflavone, corylifolinin, coryfolin, corylin, and bavachinin) were identified as potent in vitro inhibitors of CES1, with Ki values estimated as 5.3, 9.4, 1.9, 0.7, and 0.5 µM, respectively (Sun et al., 2016).

Several other naturally occurring flavonoids have also been found to modulate CES1 activity in vitro. In an HLM system, the flavones luteolin and nevadensin and the flavonol herbacetin inhibited CES1, with a range of IC50 values varying from 2.6 to 68.0 µM (Wang et al., 2018b). The Ki of nevadensin was further calculated as around 3.5 µM. In a study conducted by Shimizu et al. (2014), 100 µM wogonin, a flavonoid found in root extract of Scutellaria baicalensis, inhibited ∼60% of the hydrolytic activity of a recombinant CES1 system.

Clinical Exposure.

Naringenin can be measured in the systemic circulation after ingestion of various dietary sources, including orange juice, grapefruit juice, tomatoes, raisins, and certain herbs used in traditional medicine. Consumption of dietary naringenin via fruits and vegetables generally resulted in systemic concentrations below 200 ng/ml (Bugianesi et al., 2004; Gardana et al., 2007; Bredsdorff et al., 2010; Vallejo et al., 2010; Kanellos et al., 2013). Higher exposure was achieved by taking orange extracts or pure compound (Kanaze et al., 2007; Rebello et al., 2020). In a study reported by Rebello et al. (2020), after a single oral dose of whole-orange (Citrus sinensis) extract containing 600 mg of naringenin, a mean serum Cmax of 13.2 µg/ml was achieved in healthy volunteers (n = 18). Notably, ingestion of grapefruit juice (8 ml/kg) was also able to yield relatively high plasma concentrations (Cmax = 1.6 µg/ml) (Erlund et al., 2001). A TCM formula known as zhizhuwan (a mixture of fruits from Citrus aurantium L. or C. sinensis Osbeck and roots from Atractylodes macrocephala Koidz) achieved a Cmax of 3.16 µg/ml in healthy volunteers (n = 10) (Cao et al., 2010), whereas other tested traditional medicines generally rendered lower exposure (Xiong et al., 2014; Kitagawa et al., 2015b; Huang et al., 2019).

The bioavailability of quercetin has been extensively studied from a wide variety of sources, including onions, black tea, green tea, cranberry juice, sea buckthorn, apple, raisin, red wine, and pure compounds. Generally, ingestion of typical dietary portions achieved quercetin concentrations below 1 µg/ml in human (de Vries et al., 2001; Hollman et al., 2001; Goldberg et al., 2003; Suomela et al., 2006; Kanellos et al., 2013; McKay et al., 2015). However, relatively high Cmax of quercetin (1.1–2.3 µg/ml) was achieved in several studies after administration of onion supplement (331 µM quercetin glucosides), quercetin-4′-O-glucoside (331 µM isolated from onion), quercetin chews (RealFX Q-Plus providing 500 mg of quercetin), and dry shallot skin (1.4 mg of quercetin per kilogram) in healthy volunteers, respectively (Graefe et al., 2001; Wiczkowski et al., 2008; Kaushik et al., 2012). It should be noted that a relatively large variability in quercetin exposure has been observed between studies. Much lower systemic exposure to quercetin was observed in many other studies after onions or quercetin-containing supplements were administered (McAnlis et al., 1999; Erlund et al., 2000; Egert et al., 2008; Lee and Mitchell, 2012; Guo et al., 2014; Burak et al., 2017).

The systemic exposure to luteolin after ingestion of food supplements has been investigated in two independent studies using healthy volunteers. A plasma Cmax of 332 ng/ml luteolin was observed in healthy volunteers (n = 8) after oral administration of Chrysanthemum morifolium extract (20 mg/kg) tablets (Li et al., 2013). In the second study, oral administration of an artichoke leaf extract (containing 35.2 mg of luteolin equivalents) yielded a plasma Cmax of 157 ng/ml luteolin in healthy volunteers (n = 14) (Wittemer et al., 2005).

The exposure to kaempferol from several natural products has been investigated—namely, black/green tea, cranberry juice, sea buckthorn, red wine, onion, and raisins. The highest systemic level of kaempferol (397 ng/ml) was achieved 1 hour after consumption of sea buckthorn flavonols (Suomela et al., 2006).

Ginsenosides

The name ginseng is variously applied to a number of different commercially successful herbs that have been used for centuries for their putative health benefits. Asian ginseng (Panax ginseng) and American ginseng (Panax quinquefolius) are among the most popular products. Ginseng is generally consumed in an effort to improve overall well being, physical stamina, and immune function and to relieve a plethora of other health problems (Shergis et al., 2013). Ginsenosides are the major constituents found in ginseng.

In Vitro Studies.

Sun et al. (2019) screened the inhibitory effects of more than 20 ginsenosides on CES1 utilizing an HLM system. Among the tested ginsenosides, dammarenediol II, 20S-O-β-(d-glucosyl)-dammarenediol II, panaxadiol, and panaxatriol exhibited IC50 values <100 µM. Dammarenediol II and 20S-O-β-(d-glucosyl)-dammarenediol II had the most potent in vitro inhibition on CES1, with IC50 values of 2.1 and 2.4 µM, respectively.

Lignans

Lignans are a class of polyphenols in plants that may provide a number of health benefits, such as preventive effects from cancer, cardiovascular diseases, and diabetes (Durazzo et al., 2018). They can be found in various foods, such as seeds, whole grains, fruits, and vegetables (Adlercreutz, 2007).

In Vitro Studies.

The bark of Magnolia officinalis has been used in traditional Chinese and Japanese medicine for more than 1000 years for treating various diseases, such as anxiety, depression, headache, asthma, and gastrointestinal disorders (Poivre and Duez, 2017). Magnolol is a bioactive lignan found in magnolia bark. In a study conducted by Song et al. (2019b), magnolol exerted potent inhibition (Ki = 0.23–1.36 µM) on the hydrolysis of various substrates mediated by CES1.

Schisandra chinensis (Turcz.) Baill. is a further example of a botanical with a long history of use in TCM. This dietary supplement/medicinal agent has been used in the treatment of diseases of the gastrointestinal tract, respiratory system, cardiovascular diseases, general fatigue and weakness, insomnia, and others. S. chinensis extracts contain numerous bioactive compounds, including lignans, triterpenes, phenolic acids, flavonoids, and polysaccharides, with the dibenzocyclooctadiene lignans purported to be responsible for many of the claimed health benefits (Nowak et al., 2019). Fu et al. (2019) evaluated the inhibition of CES1 by the major lignans isolated from the fruits of S. chinensis (Turcz.) Baill. Anwuligan, schisandrol B, schisanhenol, deoxyschizandrin, and schisandrin B were included in the assessment utilizing HLMs. Schisandrin B exhibited the strongest inhibition of CES1 activity, with a calculated Ki of 29.8 µM.

Tanshinones

The dried roots of Salvia miltiorrhiza (danshen) are commonly used in TCM as a single herb or in multiherb formulations for treatment of cardiovascular and cerebrovascular diseases (Cheng, 2007). Like most botanical extracts and formulations, danshen contains numerous phytoconstituents, with more than 100 components having been isolated and structurally identified to date (Su et al., 2015).

In Vitro Studies.

Hatfield et al. (2013) demonstrated potent in vitro inhibition of recombinant CES1 by extracts of danshen roots. The extracts were further separated by chromatography, and the fraction showing the highest degree of enzyme inhibition was subject to mass spectrometry. Several tanshinones (tanshinone I, tanshinone IIA, and dihydrotanshinone) were identified as the major components, indicating their contribution to the inhibitory effects danshen extracts exhibited on CES1. When using the individual phytoconstituents, the inhibition potency of selected individual tanshinones were also evaluated in the recombinant enzyme system, with the calculated Ki ranging from 0.398 to 26.3 µM.

Clinical Exposure.

A pharmacokinetic study was conducted in healthy volunteers (n = 24) to compare exposure to tanshinones after a single oral dose of two different danshen formulations (traditional decoction vs. micronized granular powder) (Xing et al., 2017). The granular powder formulation resulted in much higher plasma concentrations of tanshinone I, tanshinone IIA, and cryptotanshinone, with mean Cmax values of 6.57, 25.8, and 146.7 ng/ml, respectively.

Triterpenoids

Natural triterpenoids are phytochemicals that have wide distribution in various plants and are presented as free triterpenoids, triterpenic glycosides, phytosterols, and their precursors (Patlolla and Rao, 2012). Pharmacologically, the most significant triterpenoid structures are oleanane, ursane, lupine, and dammarane-euphane triterpenoids, which are frequently studied for their putative therapeutic properties, such anticancer, anti-inflammatory, and immunomodulatory effects (Dzubak et al., 2006).

In Vitro Studies.

The inhibition of triterpenoids on CES1 has been reported by several studies (Zou et al., 2017; Song et al., 2019a) in which a panel of natural triterpenoids were screened in HLM. Pentacyclic triterpenoids, one of the major groups of these compounds, exhibited very potent inhibition, with IC50 values generally under 1 µM. Those pentacyclic triterpenoids include oleanolic acid (OA), ursolic acid (UA), maslinic acid, hederagenin, corosolic acid, pmolic acid, asiatic acid (AA), betulinic acid, betulinic acid-28-methyl ester, and acetylbutulinic acid. Less potent in vitro inhibition (IC50 > 1 µM) was observed for several other triterpenoids, including polygalacic acid, glycyrrhetic acid [glycyrrhetinic acid (GLA)], betulin, celastrol, pachymic acid, dehydropachymic acid, and polyporenic acid C.

Clinical Exposure.

The exposure to OA in humans has been studied from both supplements and daily food sources. The highest systemic concentration was reported by Rada et al. (2015), in which healthy subjects (n = 9) received a meal containing 30 mg of OA (dissolved in pomace olive oil). The serum Cmax of OA was achieved at 598 ng/ml. Interestingly, much lower exposure to OA (Cmax = 12 ng/ml) was observed in another study, in which a higher amount of OA (40 mg in capsules) was orally administered (Song et al., 2006). It was postulated that the oil formulation may assist with the absorption of OA in intestine. Besides intake of supplements, measurable OA was observed in systemic circulation (Cmax = 24 ng/ml) after ingestion of approximately 144 g of raisins (Kanellos et al., 2013). Only trace amount of OA was observed after consumption of apple peels and a traditional Japanese medicine (rikkunshito) (Kitagawa et al., 2015b; Stebounova et al., 2018).

UA has been proposed for treatment of various stages and types of cancers (Zou et al., 2019). Accordingly, a pharmacokinetic study was conducted in normal volunteers and patients with advanced solid tumors (Zhu et al., 2013). After intravenous administration of a nanoliposome formulation of UA in healthy volunteers (n = 8), a range of Cmax (1.84–3.46 µg/ml) was observed at three doses (37, 74, and 98 mg/m2, respectively), which were well tolerated.

The exposure to AA was reported in two different studies of Centella asiatica derivatives. Grimaldi et al. (1990) reported a Cmax of 0.7 and1.36 µg/ml in healthy males (n = 12) after a single oral dose of 30 and 60 mg total triterpenic fraction of C. asiatica, respectively. A much lower Cmax of AA (38–117 ng/ml) was observed in a single- and multiple-dose study by Songvut et al. (2019), in which healthy volunteers (n = 10 to 11) sequentially took 250 and 500 mg of an extract of C. asiatica in two different periods, respectively.

Glycyrrhizin (or glycyrrhizinic acid or glycyrrhizic acid) is a triterpenoid saponin obtained from the root extracts of licorice (Glycyrrhiza glabra) and has been found to exert a wide range of biologic effects in vitro (Pastorino et al., 2018). After oral consumption, glycyrrhizin was mainly converted to GLA by intestinal microflora and absorbed (Kim et al., 2000; Ploeger et al., 2001). The pharmacokinetics of GLA in humans has been studied after administration of various formulations. The highest exposure to GLA in humans appears to be in a study reported by Krahenbuhl et al. (1994), in which healthy volunteers (n = 6) took a single oral dose of 500, 1000, and 1500 mg of GLA. The observed mean Cmax values of GLA were 4.5, 7.0, and 9.0 µg/ml, respectively. Several studies reported the administration of an ammonium salt of glycyrrhizin diammonium glycyrrhizinate to healthy volunteers (Ding et al., 2006; Zhao et al., 2008; Zou et al., 2009). After single oral doses ranging from 100 to 150 mg diammonium glycyrrhizinate, the achieved Cmax values of GLA were generally under 100 ng/ml. Similarly, a single oral dose of 75 mg of glycyrrhizin yielded a systemic GLA concentration of 200 ng/ml (Suzuki et al., 2017). GLA ingested as a component of traditional medicines has also been reported (Takeda et al., 1990; Kitagawa et al., 2015a; Sadakane et al., 2015; Lee et al., 2020), with the highest Cmax observed at 211 ng/ml. Glycyrrhizin has recognized antiviral effects in vitro and has been administered intravenously as a potential therapeutic agent for patients with hepatitis (Kumada, 2002; Manns et al., 2012; Hung et al., 2017). In a study conducted by Tanaka et al. (1993), patients with chronic hepatitis (n = 8) received repeated intravenous daily doses of 120 mg glycyrrhizin, which rendered 0.5–1.7 µg/ml of plasma GLA 2 hours after dosing.

An average serum celastrol level of 117 ng/ml was reported in patients (n = 10) with nephrotic syndrome 2 hours after ingestion of an extract from Tripterygium wilfordii Hook. F (20 mg) (Du et al., 2019).

In the study conducted by Kitagawa and colleagues, only a traceable amount of pachymic acid (Cmax = 91 pg/ml) was detected in healthy adults (n = 19) who took oral 7.5-g doses of rikkunshito (Kitagawa et al., 2015b).

Anti-Influenza TCM Formulas

In the theory of TCM, many symptoms caused by influenza are categorized as “exterior syndrome” and are usually treated with various formulas containing multiple herbs in combination as antiviral and immunomodulating agents. Therefore, those formulas are potentially coadministered with conventional anti-influenza agents, such as oseltamivir, a well recognized prodrug known to be activated by CES1.

In Vitro Studies.

In an in vitro system comprising human recombinant CES1, Zhang et al. (2019) tested the inhibition of oseltamivir hydrolysis by 10 marker compounds from individual herbs used in the anti-influenza formulas. Epigoitrin, glycyrrhizin, and liquirtin at 10 µM were found to exert <50% inhibition.

Clinical Studies.

In a 5-day-long clinical study (n = 14) conducted by Chang et al. (2014), 10 g of an anti-influenza TCM formula given twice daily did not significantly change the pharmacokinetics of oseltamivir in healthy volunteers.

Miscellaneous

Guggul is a resin extract from Commiphora wightii that has been used in Ayurvedic medicine as a hypolipidemic agent (Deng, 2007). In a study conducted by Yang et al. (2012), both the mRNA and protein levels of CES1 were significantly induced in primary human hepatocytes treated with 10 µM of a major active phytosteroid (Z-guggulsterone) in guggul for 24 hours. The authors also tested the inductive effect of Z-guggulsterone in a human hepatic cell line (Huh7), and the induction on CES1 was found to be concentration-dependent (0–20 µM).

Ning et al. assessed the effects of gambogic acid (GA), a xanthonoid originated from Garcinia hanburyi and also present in the TCM gamboge, on carboxylesterases in two human hepatic cell lines (Huh7 and HepG2)(Ning et al., 2016). After being exposed to GA for 24 hours, the protein levels of CES1 were decreased concentration dependently in both cell lines, together with a decrease in the overall carboxylesterase activity as measured by p-NPA hydrolysis.

β-Lapachone is one of the naphthoquinones found in the inner bark of Tabebuia avellanedae (pau d’arco) and is marketed as an herbal supplement. This compound exhibited potent in vitro inhibition on recombinant CES1, with a Ki value of 1.22 µM (Hatfield et al., 2017).

Sulforaphane is a natural chemical found in many cruciferous vegetables and is believed to have antioxidant and antitumor properties (Vanduchova et al., 2019). The induction of CES1 by sulforaphane was investigated by Chen et al. (2012), in which after a 24-hour exposure to 10 µM sulforaphane, significant increases (>2-fold) in CES1 mRNA level were observed in both human primary hepatocyte and the Huh7 cell line.

In a study conducted by Liu et al. (2010) screening traditional botanical medicines of the Cree indigenous population of northern Quebec, two extracts of unspecified composition exhibited approximately 50% inhibition on CES1-mediated oseltamivir hydrolysis in an HLM system. However, minimal inhibition was observed when they were prepared in a traditional way (i.e., 1 g dried material boiled in 250 ml water). In addition, goldenseal was found to achieve approximately 75% inhibition on oseltamivir hydrolysis in their assay system, although only a single concentration of goldenseal was tested.

Resveratrol is a popular and well studied dietary supplement product belonging to polyphenols. It has high antioxidant potential and exhibits anticancer properties in vitro, and it is of interest in treating a wide variety of inflammatory conditions (Ko et al., 2017; Nunes et al., 2018). Resveratrol was found by Shimizu et al. (2014) to inhibit 60% of CES1 hydrolytic activity in a recombinant system at a concentration of 100 µM.

Clinical Exposure.

GA has undergone some development as an investigational anticancer agent in an intravenous formulation (Chi et al., 2013). After receiving a single intravenous dose (35 mg/m2), the mean Cmax of GA in patients with cancer (n = 6) was determined to be 1.88 µg/ml (Ding et al., 2007).

Exposure to sulforaphane has most frequently been assessed in studies evaluating exposures after ingestion of broccoli or broccoli products. The highest documented exposure was 656 ng/ml after 200 µM of broccoli sprout extract containing sulforaphane was orally administered to patients with melanoma (n = 5) (Tahata et al., 2018).

Resveratrol has been extensively studied using various products formulated to enhance bioavailability, with the highest Cmax (1.94 µg/ml) reported in patients with cancer after oral administration of 5 g of micronized resveratrol (Howells et al., 2011).

Discussion

Our review of the current literature indicated that a number of natural products appear to exhibit in vitro or clinical modulatory effects on CES1. To further assess the likelihood of an NPDI in humans, the potential clinical exposure to these potential CES1-modulating products was estimated by reviewing available pharmacokinetic studies and comparing these data to the respective in vitro parameters (e.g., Ki and IC50), as described in the Materials and Methods section. Figure 3 depicts the structures of those implicated compounds, and a summary of assessment was presented in Table 3, assuming clinical exposure scenarios that could produce the highest possible risk of NPDI. We considered a clinical drug interaction study as being warranted if a potential interaction was predicted in our assessment. A phase 0 study is warranted for compounds that showed in vitro inhibition but lacks pharmacokinetic data. A proposed priority list of natural compounds is presented in Table 4.

Fig. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.

Chemical structures of natural compounds that presently provide the strongest evidence of NPDI potential.

View this table:
  • View inline
  • View popup
TABLE 3

Notable examples of clinical exposure to natural products identified as CES1 modulators in studies with humanized in vitro system

View this table:
  • View inline
  • View popup
TABLE 4

Summary of clinical botanical-drug interaction potential of in vitro natural inhibitors

THC, CBD, and CBN can all potentially inhibit CES1 activity in certain clinical scenarios. A moderate interaction risk exists for THC and CBN ([I]/Ki = 0.95 and 0.14, respectively) via recreational use (i.e., smoking or vaporizing) of cannabis cigarettes. The risk is higher for THC mainly because of its higher content (and thus higher exposure) in users of cannabis cigarettes. The systemic CBD concentration achieved by smoking cannabis is not likely to cause inhibition on CES1, as evidence by a [I]/Ki value <0.012. However, a high and moderate interaction risk is expected through oral administration of CBD as Epidiolex ([I]/Ki = 2.4) and a dietary supplement ([I]/Ki = 0.25), respectively.

Moderate to high interaction risk is predicted for naringenin under various clinical occasions. Generally, consumption of fruits and vegetables does not produce sufficiently high naringenin concentrations in humans and is thereby free of interaction concerns ([I]/IC50 < 0.03). On the contrary, the [I]/IC50 value is well above 1 after ingestion of whole-orange extract containing naringenin. Given the interest in its therapeutic effects on glucose and lipid metabolism, naringenin is likely to be taken in forms of botanical extracts or purified compounds, making the drug interaction plausible. In addition, grapefruit juice and the TCM formula zhizhuwan can also yield systemic concentrations of naringenin that are of moderate BDI risk. Besides naringenin, quercetin and luteolin are two other flavonoids that can have potential clinical interaction with CES1. Similar to naringenin, quercetin acquired from the consumption of a typical diet is of low BDI risk. However, it could theoretically produce a moderate inhibition of CES1 after the ingestion of quercetin supplements ([I]/IC50 = 0.23). Oral consumption of dietary supplements containing luteolin also appears to achieve sufficient systemic levels of luteolin exerting moderate inhibition on CES1 ([I]/IC50 = 0.22).

The risk of a clinical interaction between danshen and CES1 is considered moderate. This is mainly due to the presence of cryptotanshinone ([I]/Ki = 0.91) after the administration of a micronized granular powder formulation of Danshen. We were unable to find any documentation of human exposure to two of the identified tanshinones (dihydrotanshinone and miltirone); thus, their clinical inhibitory potential remains unknown and a matter of speculation. Interestingly, it appears that drug interactions caused by danshen products may be complex, and its modulatory effects on CES1 could be potentially masked. In a study of healthy volunteers conducted by Zhou et al. (2018), the clearance of clopidogrel and its active metabolite were significantly increased after a 7-day administration of danshen capsules. This result appears to contradict the results of the aforementioned in vitro study in that decreased CES1 activity would be anticipated to increase the exposure to clopidogrel and its active metabolite. Thus, the danshen-clopidogrel interaction may require further assessment with consideration to all DMEs contributing to clopidogrel biotransformation. Cryptotanshinone or tanshinone IIA has been further studied and found to induce the expression of CYP3A4 in a human hepatic cell line (HepG2). The observed phenomenon was concluded as a consequence of P450 induction by tanshinones. It is noteworthy that tanshinones were also found to exert modulatory effects on a variety of metabolic enzymes and transporters besides CES1 (Chen et al., 2017).

A high risk of NPDI is predicted for several triterpenoids for which very potent in vitro inhibition on CES1 (i.e., IC50 < 0.64 µM) was observed. Consumption of OA as a dietary supplement, especially taken with certain oil-based formulations, appears to represent the highest BDI risk ([I]/IC50 = 4.7). In addition, OA from raisins also has the potential to affect activity of CES1 in humans, although the extent is expected to be much lower ([I]/IC50 = 0.19). The exposure to AA has been studied after intake of C. asiatica supplements, which suggests a high potential of BDI when compared with the in vitro parameter ([I]/IC50 = 4.3). Notably, the studies also indicated that chronic consumption of C. asiatica supplements could lead to accumulation of AA in the circulation (Grimaldi et al., 1990; Songvut et al., 2019).

Although the intravenous administration of any botanically derived compound is uncommon, there are circumstances in which it does occur, and the implications are discussed accordingly. UA and GLA are two triterpenoids with which a clinical interaction could potentially occur after intravenous administration. The physiologic concentration of UA achieved after an intravenous dose well exceeds 1 ([I]/IC50 = 32), suggesting high risk of drug interactions. For GLA, its highest reported systemic level was achieved after the ingestion of capsules containing 500–1500 mg of pure GLA. However, such exposures are unlikely to occur under conditions of typical dietary intake. The use of licorice root extracts has been associated with several adverse effects, and consequently, a daily consumption below 100 mg of GLA is recommended (Omar et al., 2012). Daily oral intake of GLA from other sources (e.g., supplements, confectionery products, and traditional medicines) is generally not expected to affect CES1 activity ([I]/IC50 ≤ 0.04). However, intravenously administered glycyrrhizin delivers high enough GLA that it is of moderate BDI risk ([I]/IC50 = 0.28). UA and GLA are formulated as an intravenous dose because of their purported anticancer and antiviral effects, respectively (Kumada, 2002; Manns et al., 2012; Hung et al., 2017; Zou et al., 2019). Although the use of UA and GLA for these medical purposes is largely investigational at present, a significant risk of BDI is posed, requiring further research.

Beyond the aforementioned natural compounds and formulations, human pharmacokinetic studies have been conducted with the following compounds: kaempferol, celastrol, pachymic acid, and resveratrol. The existing pharmacokinetic studies do not support any of them being a clinical modulator of CES1 (i.e., [I]/Ki or IC50 < 0.1). However, it should be noted that only one pharmacokinetic study is available for celastrol and pachymic acid. A higher physiologic concentration of these compounds may be attainable through consumption of other formulations that are as yet unstudied. If this is eventually documented to be the case, further assessment may be warranted at that time.

For natural compounds showing modulatory effects on the expression of CES1 (i.e., Z-guggulsterone, GA, and sulforaphane), the maximum inductive effects and the half-maximum inductive/inhibitory concentrations should be further investigated for a more accurate evaluation. Here, we made the assessment and judgment of whether existing literature supported the possibility of achieving the in vitro concentrations physiologically. No human pharmacokinetic study of Z-guggulsterone could be identified. The intravenous administration of GA may exert clinical effects on CES1, as suggested by an achieved systemic concentration of 3.0 µM (Cmax), a concentration higher than that tested in the in vitro assay (0.75 µM), whereas sulforaphane only achieved a Cmax of 3.7 µM, which was well below the in vitro concentration (10 µM).

Subcellular systems (e.g., liver microsomes and recombinant enzymes) were employed in most of the in vitro studies reviewed. One major limitation of these systems is the inability to detect any effects from chronic exposure to the given natural products, which is a common practice in real life. Although we did not include any results of animal studies in this review, we are aware of the modulatory effects of one or more natural constituents from danshen and ginseng products on CES1 expression (i.e., downregulation) in Sprague-Dawley rat livers (Ma et al., 2018; Ji et al., 2019). Existence of such a mechanism may either intensify or counteract the chemical interaction with CES1, highlighting the need of more-thorough research. Another consideration with chronic administration of natural products is the potential accumulation of phytoconstituents. Notably, many pharmacokinetic parameters (i.e., Cmax) used in our assessments were measurements from single-dose exposure studies rather than at steady state. Thus, an underestimation of BDI liability is possible.

Several interaction studies on Sprague-Dawley rats were found but were not included in this review. Although animal models generally provide useful information, caution should be given when making direct clinical predictions. In the study conducted by Chang et al. (2014), the anti-influenza formula of TCM only exerted minimal impact on the pharmacokinetics of oseltamivir in healthy volunteers despite a positive interaction identified in rats. This observation highlights a potential interspecies difference in the pharmacokinetics of either the inhibitor, substrate, or both. The difference in tissue distribution and substrate specificity of carboxylesterases between human and other species has also been well established (Hosokawa, 2008; Lian et al., 2018; Wang et al., 2018a; Kisui et al., 2020). Notably, CES1 is found abundantly in the blood of rodents but not humans, representing a site of metabolism beyond the liver in rodents. In addition, both substrate and inhibitor can be differentially metabolized or transported between animal and human, which warrants the examination of interspecies difference of other DMEs and transporters when making such BDI predictions from animal studies.

It is a given that natural products contain a multitude of constituents. Many of the compounds from a plant source may exert similar or potentially additive or synergistic effects on an enzyme system or drug transporter in vitro, but the in vivo effects (if any) will be highly dependent on the bioavailability of each. In the case of the major cannabinoids THC, CBD, and CBN, all are generally detectable after smoking cannabis cigarettes, and all produce some degree of CES1 inhibition in vitro. Although the ultimate clinical effects on CES1 have yet to be evaluated, the possibility of additive effects must be considered. In another example, after the consumption of raisins, several flavonoids, including kaempferol, quercetin, and naringenin, were simultaneously present in plasma (Kanellos et al., 2013), each potentially contributing its own individual influence, suggesting the potential for additive influences on CES1 activity. Additionally, TCMs generally consist of a very complex mixture of botanicals so that concurrent exposure to multiple natural compounds ensues after administration. Therefore, a combination of modulatory effects by constituents should not be ruled out, nor the possibility of certain constituents producing opposite effects on an enzyme system in a somewhat “push-pull” influence, resulting in a net effect that is not easily predicted by existing models.

In conclusion, the available data on modulation of CES1 activity by natural products are limited compared with P450 and UGT assessments. However, there has been a recent accumulation of evaluable research reports. Not unexpectedly, published reports were primarily limited to results of in vitro investigations with almost no follow-up clinical assessments available. Although it cannot be emphasized enough that all in vitro findings must be confirmed by direct clinical assessment using appropriately designed studies, some potential CES1 interactions appear more likely than others. Moderate to high risk of clinical interactions was concluded by using cannabis products (THC, CBD, and CBN) via smoking or oral routes, supplements containing various flavonoids (naringenin, quercetin, and luteolin) and triterpenoids (OA and AA), and certain traditional medicines (danshen and zhizhuwan). In addition, UA, GLA, and GA when used intravenously are able to achieve systemic concentrations high enough to potentially cause a BDI. A clinical drug interaction study can be prioritized for these products. Many other natural compounds have been documented to exhibit potent CES1 inhibition (Ki or IC50 <1 µM) or induction in in vitro studies (corylin, bavachinin, magnolol, maslinic acid, hederagenin, corosolic acid, pomolic acid, betulinic acid and its derivatives). However, we were not able to make similar statements about the potential clinical impact of these many compounds because of the lack of pharmacokinetic information on human exposures. A phase 0 study should be prioritized for these products. Lastly, several products appear to be able to modulate the expression of CES1 when administered chronically, an observation warranting additional study.

Authorship Contributions

Performed data analysis: Qian, Markowitz.

Wrote or contributed to the writing of the manuscript: Qian, Markowitz.

Footnotes

    • Received April 6, 2020.
    • Accepted June 12, 2020.
  • https://doi.org/10.1124/dmd.120.000065.

Abbreviations

AA
asiatic acid
BDI
botanical-drug interactions
CBD
cannabidiol
CBN
cannabinol
CES
carboxylesterase
DME
drug-metabolizing enzyme
GA
gambogic acid
GLA
glycyrrhetic acid
HLM
human liver microsome [I]; the maximum plasma level of inhibitor encountered in vivo
NPDI
natural product–drug interaction
OA
oleanolic acid NPA; p-NPA para-nitrophenyl acetate
P450
cytochrome P450
TCM
traditional Chinese medicine
THC
∆9-tetrahydrocannabinol
UA
ursolic acid
UGT
UDP-glucuronosyltransferase
  • Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    1. Adlercreutz H
    (2007) Lignans and human health. Crit Rev Clin Lab Sci 44:483–525.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Atsmon J,
    2. Heffetz D,
    3. Deutsch L,
    4. Deutsch F, and
    5. Sacks H
    (2018) Single-dose pharmacokinetics of oral cannabidiol following administration of PTL101: a new formulation based on gelatin matrix pellets technology. Clin Pharmacol Drug Dev 7:751–758.
    OpenUrl
  3. ↵
    1. Bachmann KA and
    2. Lewis JD
    (2005) Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants. Ann Pharmacother 39:1064–1072.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Bailey DG,
    2. Dresser G, and
    3. Arnold JM
    (2013) Grapefruit-medication interactions: forbidden fruit or avoidable consequences? CMAJ 185:309–316.
    OpenUrlFREE Full Text
  5. ↵
    1. Bailey DG,
    2. Malcolm J,
    3. Arnold O, and
    4. Spence JD
    (1998) Grapefruit juice-drug interactions. Br J Clin Pharmacol 46:101–110.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Bredsdorff L,
    2. Nielsen IL,
    3. Rasmussen SE,
    4. Cornett C,
    5. Barron D,
    6. Bouisset F,
    7. Offord E, and
    8. Williamson G
    (2010) Absorption, conjugation and excretion of the flavanones, naringenin and hesperetin from alpha-rhamnosidase-treated orange juice in human subjects. Br J Nutr 103:1602–1609.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Bridgeman MB and
    2. Abazia DT
    (2017) Medicinal cannabis: history, pharmacology, and implications for the acute care setting. P&T 42:180–188.
    OpenUrl
  8. ↵
    1. Bugianesi R,
    2. Salucci M,
    3. Leonardi C,
    4. Ferracane R,
    5. Catasta G,
    6. Azzini E, and
    7. Maiani G
    (2004) Effect of domestic cooking on human bioavailability of naringenin, chlorogenic acid, lycopene and beta-carotene in cherry tomatoes. Eur J Nutr 43:360–366.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Burak C,
    2. Brüll V,
    3. Langguth P,
    4. Zimmermann BF,
    5. Stoffel-Wagner B,
    6. Sausen U,
    7. Stehle P,
    8. Wolffram S, and
    9. Egert S
    (2017) Higher plasma quercetin levels following oral administration of an onion skin extract compared with pure quercetin dihydrate in humans. Eur J Nutr 56:343–353.
    OpenUrl
  10. ↵
    1. Cao H,
    2. Chen X,
    3. Sun H,
    4. Sakurai T,
    5. Zhou J,
    6. Sun W,
    7. Lv H, and
    8. Wang X
    (2010) Pharmacokinetics-based elucidation on disparity in clinical effectiveness between varieties of Zhi Zhu Wan, a Traditional Chinese Medical formula. J Ethnopharmacol 128:606–610.
    OpenUrlPubMed
  11. ↵
    1. Cellini M,
    2. Attipoe S,
    3. Seales P,
    4. Gray R,
    5. Ward A,
    6. Stephens M, and
    7. Deuster PA
    (2013) Dietary supplements: physician knowledge and adverse event reporting. Med Sci Sports Exerc 45:23–28.
    OpenUrlCrossRef
  12. ↵
    1. Chang Q,
    2. Wo S,
    3. Ngai KL,
    4. Wang X,
    5. Fok B,
    6. Ngan TM,
    7. Wong VT,
    8. Chan TY,
    9. Lee VH,
    10. Tomlinson B, et al.
    (2014) Bench to bed evidences for pharmacokinetic and pharmacodynamic interactions involving oseltamivir and Chinese medicine. Evid Based Complement Alternat Med 2014:354172.
    OpenUrl
  13. ↵
    1. Chen F,
    2. Li L, and
    3. Tian DD
    (2017) Salvia miltiorrhiza roots against cardiovascular disease: consideration of herb-drug interactions. BioMed Res Int 2017:9868694.
    OpenUrl
  14. ↵
    1. Chen YT,
    2. Shi D,
    3. Yang D, and
    4. Yan B
    (2012) Antioxidant sulforaphane and sensitizer trinitrobenzene sulfonate induce carboxylesterase-1 through a novel element transactivated by nuclear factor-E2 related factor-2. Biochem Pharmacol 84:864–871.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Cheng TO
    (2007) Cardiovascular effects of danshen. Int J Cardiol 121:9–22.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Chi Y,
    2. Zhan XK,
    3. Yu H,
    4. Xie GR,
    5. Wang ZZ,
    6. Xiao W,
    7. Wang YG,
    8. Xiong FX,
    9. Hu JF,
    10. Yang L, et al.
    (2013) An open-labeled, randomized, multicenter phase IIa study of gambogic acid injection for advanced malignant tumors. Chin Med J (Engl) 126:1642–1646.
    OpenUrlPubMed
  17. ↵
    1. Cox EJ,
    2. Maharao N,
    3. Patilea-Vrana G,
    4. Unadkat JD,
    5. Rettie AE,
    6. McCune JS, and
    7. Paine MF
    (2019) A marijuana-drug interaction primer: precipitants, pharmacology, and pharmacokinetics. Pharmacol Ther 201:25–38.
    OpenUrl
  18. ↵
    1. Deng R
    (2007) Therapeutic effects of guggul and its constituent guggulsterone: cardiovascular benefits. Cardiovasc Drug Rev 25:375–390.
    OpenUrlPubMed
  19. ↵
    1. Desrosiers NA,
    2. Himes SK,
    3. Scheidweiler KB,
    4. Concheiro-Guisan M,
    5. Gorelick DA, and
    6. Huestis MA
    (2014) Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin Chem 60:631–643.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. de Vries JH,
    2. Hollman PC,
    3. van Amersfoort I,
    4. Olthof MR, and
    5. Katan MB
    (2001) Red wine is a poor source of bioavailable flavonols in men. J Nutr 131:745–748.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Di L
    (2019) The impact of carboxylesterases in drug metabolism and pharmacokinetics. Curr Drug Metab 20:91–102.
    OpenUrl
  22. ↵
    1. Ding L,
    2. Huang D,
    3. Wang J, and
    4. Li S
    (2007) Determination of gambogic acid in human plasma by liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 846:112–118.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Ding L,
    2. Huang X,
    3. Yang J,
    4. Bian X,
    5. Zhang Z, and
    6. Liu G
    (2006) Determination of glycyrrhetic acid in human plasma by LC-ESI-MS. J Pharm Biomed Anal 40:758–762.
    OpenUrlPubMed
  24. ↵
    1. Du X,
    2. He X,
    3. Huang Y,
    4. Fu B,
    5. Liang B,
    6. Lv C,
    7. Li Y,
    8. Gao X, and
    9. Wang Y
    (2019) Simultaneous determination of seven effective components of Tripterygium glycosides in human biological matrices by ultra performance liquid chromatography-triple quadrupole mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 1113:1–13.
    OpenUrl
  25. ↵
    1. Durazzo A,
    2. Lucarini M,
    3. Camilli E,
    4. Marconi S,
    5. Gabrielli P,
    6. Lisciani S,
    7. Gambelli L,
    8. Aguzzi A,
    9. Novellino E,
    10. Santini A, et al.
    (2018) Dietary lignans: definition, description and research trends in databases development. Molecules 23:23.
    OpenUrl
  26. ↵
    1. Dzubak P,
    2. Hajduch M,
    3. Vydra D,
    4. Hustova A,
    5. Kvasnica M,
    6. Biedermann D,
    7. Markova L,
    8. Urban M, and
    9. Sarek J
    (2006) Pharmacological activities of natural triterpenoids and their therapeutic implications. Nat Prod Rep 23:394–411.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Egert S,
    2. Wolffram S,
    3. Bosy-Westphal A,
    4. Boesch-Saadatmandi C,
    5. Wagner AE,
    6. Frank J,
    7. Rimbach G, and
    8. Mueller MJ
    (2008) Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J Nutr 138:1615–1621.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Erlund I,
    2. Kosonen T,
    3. Alfthan G,
    4. Mäenpää J,
    5. Perttunen K,
    6. Kenraali J,
    7. Parantainen J, and
    8. Aro A
    (2000) Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol 56:545–553.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Erlund I,
    2. Meririnne E,
    3. Alfthan G, and
    4. Aro A
    (2001) Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. J Nutr 131:235–241.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Ferrer JL,
    2. Austin MB,
    3. Stewart C Jr.., and
    4. Noel JP
    (2008) Structure and function of enzymes involved in the biosynthesis of phenylpropanoids. Plant Physiol Biochem 46:356–370.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Fu Q,
    2. Yang K,
    3. Hu RX,
    4. Du Z,
    5. Hu CM, and
    6. Zhang X
    (2019) Evaluation of the inhibition of human carboxylesterases (CESs) by the active ingredients from Schisandra chinensis. Xenobiotica 49:1260–1268.
    OpenUrl
  32. ↵
    1. Gardana C,
    2. Guarnieri S,
    3. Riso P,
    4. Simonetti P, and
    5. Porrini M
    (2007) Flavanone plasma pharmacokinetics from blood orange juice in human subjects. Br J Nutr 98:165–172.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Goldberg DM,
    2. Yan J, and
    3. Soleas GJ
    (2003) Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 36:79–87.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Graefe EU,
    2. Wittig J,
    3. Mueller S,
    4. Riethling AK,
    5. Uehleke B,
    6. Drewelow B,
    7. Pforte H,
    8. Jacobasch G,
    9. Derendorf H, and
    10. Veit M
    (2001) Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol 41:492–499.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Grimaldi R,
    2. De Ponti F,
    3. D’Angelo L,
    4. Caravaggi M,
    5. Guidi G,
    6. Lecchini S,
    7. Frigo GM, and
    8. Crema A
    (1990) Pharmacokinetics of the total triterpenic fraction of Centella asiatica after single and multiple administrations to healthy volunteers. A new assay for asiatic acid. J Ethnopharmacol 28:235–241.
    OpenUrlPubMed
  36. ↵
    1. Guo Y,
    2. Mah E, and
    3. Bruno RS
    (2014) Quercetin bioavailability is associated with inadequate plasma vitamin C status and greater plasma endotoxin in adults. Nutrition 30:1279–1286.
    OpenUrl
  37. ↵
    1. Gurley BJ,
    2. Yates CR, and
    3. Markowitz JS
    (2018) “…Not intended to diagnose, treat, cure or prevent any disease.” 25 years of botanical dietary supplement research and the lessons learned. Clin Pharmacol Ther 104:470–483.
    OpenUrl
  38. ↵
    1. Hanley MJ,
    2. Cancalon P,
    3. Widmer WW, and
    4. Greenblatt DJ
    (2011) The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol 7:267–286.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Hatfield MJ,
    2. Chen J,
    3. Fratt EM,
    4. Chi L,
    5. Bollinger JC,
    6. Binder RJ,
    7. Bowling J,
    8. Hyatt JL,
    9. Scarborough J,
    10. Jeffries C, et al.
    (2017) Selective inhibitors of human liver carboxylesterase based on a β-lapachone scaffold: novel reagents for reaction profiling. J Med Chem 60:1568–1579.
    OpenUrl
  40. ↵
    1. Hatfield MJ,
    2. Tsurkan L,
    3. Garrett M,
    4. Shaver TM,
    5. Hyatt JL,
    6. Edwards CC,
    7. Hicks LD, and
    8. Potter PM
    (2011) Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11. Biochem Pharmacol 81:24–31.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Hatfield MJ,
    2. Tsurkan LG,
    3. Hyatt JL,
    4. Edwards CC,
    5. Lemoff A,
    6. Jeffries C,
    7. Yan B, and
    8. Potter PM
    (2013) Modulation of esterified drug metabolism by tanshinones from Salvia miltiorrhiza (“Danshen”). J Nat Prod 76:36–44.
    OpenUrlCrossRef
  42. ↵
    1. He B,
    2. Shi J,
    3. Wang X,
    4. Jiang H, and
    5. Zhu HJ
    (2019) Label-free absolute protein quantification with data-independent acquisition. J Proteomics 200:51–59.
    OpenUrl
  43. ↵
    1. Her L and
    2. Zhu HJ
    (2020) Carboxylesterase 1 and precision pharmacotherapy: pharmacogenetics and nongenetic regulators. Drug Metab Dispos 48:230–244.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Hobbs JM,
    2. Vazquez AR,
    3. Remijan ND,
    4. Trotter RE,
    5. McMillan TV,
    6. Freedman KE,
    7. Wei Y,
    8. Woelfel KA,
    9. Arnold OR,
    10. Wolfe LM, et al.
    (2020) Evaluation of pharmacokinetics and acute anti-inflammatory potential of two oral cannabidiol preparations in healthy adults. Phytother Res DOI: 10.1002/ptr.6651 [published ahead of print].
  45. ↵
    1. Hollman PC,
    2. Van Het Hof KH,
    3. Tijburg LB, and
    4. Katan MB
    (2001) Addition of milk does not affect the absorption of flavonols from tea in man. Free Radic Res 34:297–300.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Holmes RS,
    2. Wright MW,
    3. Laulederkind SJ,
    4. Cox LA,
    5. Hosokawa M,
    6. Imai T,
    7. Ishibashi S,
    8. Lehner R,
    9. Miyazaki M,
    10. Perkins EJ, et al.
    (2010) Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins. Mamm Genome 21:427–441.
    OpenUrlCrossRefPubMed
  47. ↵
    1. Hosokawa M
    (2008) Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules 13:412–431.
    OpenUrlCrossRefPubMed
  48. ↵
    1. Hosokawa M and
    2. Satoh T
    (1988) Effects of hypophysectomy and pituitary hormones on hepatic microsomal carboxylesterase isozymes in male rats. Res Commun Chem Pathol Pharmacol 62:279–288.
    OpenUrlPubMed
  49. ↵
    1. Howells LM,
    2. Berry DP,
    3. Elliott PJ,
    4. Jacobson EW,
    5. Hoffmann E,
    6. Hegarty B,
    7. Brown K,
    8. Steward WP, and
    9. Gescher AJ
    (2011) Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila) 4:1419–1425.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Huang X,
    2. Xu J,
    3. He J,
    4. Shi S,
    5. Yan H,
    6. Wang J, and
    7. Ren P
    (2019) Pharmacokinetic study of the prokinetic ABCs liquiritigenin, naringenin and hesperitin following the oral administration of Si-Ni-San decoction to functional dyspepsia patients. Xenobiotica 49:708–717.
    OpenUrl
  51. ↵
    1. Huestis MA,
    2. Henningfield JE, and
    3. Cone EJ
    (1992) Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 16:276–282.
    OpenUrlCrossRefPubMed
  52. ↵
    1. Hung CH,
    2. Kee KM,
    3. Chen CH,
    4. Tseng PL,
    5. Tsai MC,
    6. Chen CH,
    7. Wang JH,
    8. Chang KC,
    9. Kuo YH,
    10. Yen YH, et al.
    (2017) A randomized controlled trial of glycyrrhizin plus tenofovir vs. tenofovir in chronic hepatitis B with severe acute exacerbation. Clin Transl Gastroenterol 8:e104.
    OpenUrl
  53. ↵
    1. Imai T,
    2. Taketani M,
    3. Shii M,
    4. Hosokawa M, and
    5. Chiba K
    (2006) Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine. Drug Metab Dispos 34:1734–1741.
    OpenUrlAbstract/FREE Full Text
  54. ↵
    1. Ji S,
    2. Shao X,
    3. Su ZY,
    4. Ji L,
    5. Wang YJ,
    6. Ma YS,
    7. Zhao L,
    8. Du Y,
    9. Guo MZ, and
    10. Tang DQ
    (2019) Segmented scan modes and polarity-based LC-MS for pharmacokinetic interaction study between fufang danshen dripping pill and clopidogrel bisulfate tablet. J Pharm Biomed Anal 174:367–375.
    OpenUrl
  55. ↵
    1. Johnson EJ,
    2. González-Peréz V,
    3. Tian DD,
    4. Lin YS,
    5. Unadkat JD,
    6. Rettie AE,
    7. Shen DD,
    8. McCune JS, and
    9. Paine MF
    (2018) Selection of priority natural products for evaluation as potential precipitants of natural product-drug interactions: a NaPDI center recommended approach. Drug Metab Dispos 46:1046–1052.
    OpenUrlAbstract/FREE Full Text
  56. ↵
    1. Kanaze FI,
    2. Bounartzi MI,
    3. Georgarakis M, and
    4. Niopas I
    (2007) Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. Eur J Clin Nutr 61:472–477.
    OpenUrlPubMed
  57. ↵
    1. Kanellos PT,
    2. Kaliora AC,
    3. Gioxari A,
    4. Christopoulou GO,
    5. Kalogeropoulos N, and
    6. Karathanos VT
    (2013) Absorption and bioavailability of antioxidant phytochemicals and increase of serum oxidation resistance in healthy subjects following supplementation with raisins. Plant Foods Hum Nutr 68:411–415.
    OpenUrl
  58. ↵
    1. Kaushik D,
    2. O’Fallon K,
    3. Clarkson PM,
    4. Dunne CP,
    5. Conca KR, and
    6. Michniak-Kohn B
    (2012) Comparison of quercetin pharmacokinetics following oral supplementation in humans. J Food Sci 77:H231–H238.
    OpenUrl
  59. ↵
    1. Kim DH,
    2. Hong SW,
    3. Kim BT,
    4. Bae EA,
    5. Park HY, and
    6. Han MJ
    (2000) Biotransformation of glycyrrhizin by human intestinal bacteria and its relation to biological activities. Arch Pharm Res 23:172–177.
    OpenUrlCrossRefPubMed
  60. ↵
    1. Kisui F,
    2. Fukami T,
    3. Nakano M, and
    4. Nakajima M
    (2020) Strain and sex differences in drug hydrolase activities in rodent livers. Eur J Pharm Sci 142:105143.
    OpenUrl
  61. ↵
    1. Kitagawa H,
    2. Munekage M,
    3. Ichikawa K,
    4. Fukudome I,
    5. Munekage E,
    6. Takezaki Y,
    7. Matsumoto T,
    8. Igarashi Y,
    9. Hanyu H, and
    10. Hanazaki K
    (2015a) Pharmacokinetics of active components of yokukansan, a traditional Japanese herbal medicine after a single oral administration to healthy Japanese volunteers: a cross-over, randomized study. PLoS One 10:e0131165.
    OpenUrl
  62. ↵
    1. Kitagawa H,
    2. Munekage M,
    3. Matsumoto T,
    4. Sadakane C,
    5. Fukutake M,
    6. Aoki K,
    7. Watanabe J,
    8. Maemura K,
    9. Hattori T,
    10. Kase Y, et al.
    (2015b) Pharmacokinetic profiles of active ingredients and its metabolites derived from Rikkunshito, a ghrelin enhancer, in healthy Japanese volunteers: a cross-over, randomized study. PLoS One 10:e0133159.
    OpenUrlPubMed
  63. ↵
    1. Knaub K,
    2. Sartorius T,
    3. Dharsono T,
    4. Wacker R,
    5. Wilhelm M, and
    6. Schön C
    (2019) A novel self-emulsifying drug delivery system (SEDDS) based on VESIsorb® formulation technology improving the oral bioavailability of cannabidiol in healthy subjects. Molecules 24:2967.
    OpenUrl
  64. ↵
    1. Ko JH,
    2. Sethi G,
    3. Um JY,
    4. Shanmugam MK,
    5. Arfuso F,
    6. Kumar AP,
    7. Bishayee A, and
    8. Ahn KS
    (2017) The role of resveratrol in cancer therapy. Int J Mol Sci 18:2589.
    OpenUrl
  65. ↵
    1. Krähenbühl S,
    2. Hasler F,
    3. Frey BM,
    4. Frey FJ,
    5. Brenneisen R, and
    6. Krapf R
    (1994) Kinetics and dynamics of orally administered 18 beta-glycyrrhetinic acid in humans. J Clin Endocrinol Metab 78:581–585.
    OpenUrlCrossRefPubMed
  66. ↵
    1. Kumada H
    (2002) Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma. Oncology 62 (Suppl 1):94–100.
    OpenUrlPubMed
  67. ↵
    1. Lee J and
    2. Mitchell AE
    (2012) Pharmacokinetics of quercetin absorption from apples and onions in healthy humans. J Agric Food Chem 60:3874–3881.
    OpenUrlPubMed
  68. ↵
    1. Lee SY,
    2. Jeong JH,
    3. Kim BN,
    4. Park SJ,
    5. Park YC, and
    6. Lee GY
    (2020) LC-MS/MS analysis of puerarin and 18β-glycyrrhetinic acid in human plasma after oral administration of Samso-eum and its application to pharmacokinetic study. Biomed Chromatogr 34:e4774.
    OpenUrl
  69. ↵
    1. Lewis JP,
    2. Horenstein RB,
    3. Ryan K,
    4. O’Connell JR,
    5. Gibson Q,
    6. Mitchell BD,
    7. Tanner K,
    8. Chai S,
    9. Bliden KP,
    10. Tantry US, et al.
    (2013) The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics 23:1–8.
    OpenUrlCrossRefPubMed
  70. ↵
    1. Li LP,
    2. Wu XD,
    3. Chen ZJ,
    4. Sun SY,
    5. Ye JF,
    6. Zeng S, and
    7. Jiang HD
    (2013) Interspecies difference of luteolin and apigenin after oral administration of Chrysanthemum morifolium extract and prediction of human pharmacokinetics. Pharmazie 68:195–200.
    OpenUrl
  71. ↵
    1. Li P,
    2. Callery PS,
    3. Gan LS, and
    4. Balani SK
    (2007) Esterase inhibition by grapefruit juice flavonoids leading to a new drug interaction. Drug Metab Dispos 35:1203–1208.
    OpenUrlAbstract/FREE Full Text
  72. ↵
    1. Lian J,
    2. Nelson R, and
    3. Lehner R
    (2018) Carboxylesterases in lipid metabolism: from mouse to human. Protein Cell 9:178–195.
    OpenUrlPubMed
  73. ↵
    1. Lindgren JE,
    2. Ohlsson A,
    3. Agurell S,
    4. Hollister L, and
    5. Gillespie H
    (1981) Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. Psychopharmacology (Berl) 74:208–212.
    OpenUrlCrossRefPubMed
  74. ↵
    1. Liu R,
    2. Tam TW,
    3. Mao J,
    4. Saleem A,
    5. Krantis A,
    6. Arnason JT, and
    7. Foster BC
    (2010) The effect of natural health products and traditional medicines on the activity of human hepatic microsomal-mediated metabolism of oseltamivir. J Pharm Pharm Sci 13:43–55.
    OpenUrlPubMed
  75. ↵
    1. Ma S,
    2. Dai G,
    3. Bi X,
    4. Gong M,
    5. Miao C,
    6. Chen H,
    7. Gao L,
    8. Zhao W,
    9. Liu T, and
    10. Zhang N
    (2018) The herb-drug interaction of clopidogrel and xuesaitong dispersible tablet by modulation of the pharmacodynamics and liver carboxylesterase 1A metabolism. Evid Based Complement Alternat Med 2018:5651989.
    OpenUrl
  76. ↵
    1. Manns MP,
    2. Wedemeyer H,
    3. Singer A,
    4. Khomutjanskaja N,
    5. Dienes HP,
    6. Roskams T,
    7. Goldin R,
    8. Hehnke U,
    9. Inoue H, and European SNMC Study Group
    (2012) Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks. J Viral Hepat 19:537–546.
    OpenUrlCrossRefPubMed
  77. ↵
    1. Markowitz JS,
    2. Donovan JL,
    3. DeVane CL,
    4. Taylor RM,
    5. Ruan Y,
    6. Wang JS, and
    7. Chavin KD
    (2003) Effect of St John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 290:1500–1504.
    OpenUrlCrossRefPubMed
  78. ↵
    1. Markowitz JS,
    2. von Moltke LL, and
    3. Donovan JL
    (2008) Predicting interactions between conventional medications and botanical products on the basis of in vitro investigations. Mol Nutr Food Res 52:747–754.
    OpenUrlPubMed
  79. ↵
    1. McAnlis GT,
    2. McEneny J,
    3. Pearce J, and
    4. Young IS
    (1999) Absorption and antioxidant effects of quercetin from onions, in man. Eur J Clin Nutr 53:92–96.
    OpenUrlCrossRefPubMed
  80. ↵
    1. McKay DL,
    2. Chen CY,
    3. Zampariello CA, and
    4. Blumberg JB
    (2015) Flavonoids and phenolic acids from cranberry juice are bioavailable and bioactive in healthy older adults. Food Chem 168:233–240.
    OpenUrlCrossRefPubMed
  81. ↵
    1. Mehmedic Z,
    2. Chandra S,
    3. Slade D,
    4. Denham H,
    5. Foster S,
    6. Patel AS,
    7. Ross SA,
    8. Khan IA, and
    9. ElSohly MA
    (2010) Potency trends of Δ9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 55:1209–1217.
    OpenUrlCrossRefPubMed
  82. ↵
    1. Moore LB,
    2. Goodwin B,
    3. Jones SA,
    4. Wisely GB,
    5. Serabjit-Singh CJ,
    6. Willson TM,
    7. Collins JL, and
    8. Kliewer SA
    (2000) St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97:7500–7502.
    OpenUrlAbstract/FREE Full Text
  83. ↵
    1. Newmeyer MN,
    2. Swortwood MJ,
    3. Barnes AJ,
    4. Abulseoud OA,
    5. Scheidweiler KB, and
    6. Huestis MA
    (2016) Free and glucuronide whole blood cannabinoids’ pharmacokinetics after controlled smoked, vaporized, and oral cannabis administration in frequent and occasional cannabis users: identification of recent cannabis intake. Clin Chem 62:1579–1592.
    OpenUrlAbstract/FREE Full Text
  84. ↵
    1. Ning Rui,
    2. Wang Xiao-Ping,
    3. Zhan Yun-Ran,
    4. Qi Qi,
    5. Huang Xue-Feng,
    6. Hu Gang,
    7. Guo Qing-Long,
    8. Liu Wei, and
    9. Yang Jian
    (2016) Gambogic acid potentiates clopidogrel-induced apoptosis and attenuates irinotecan-induced apoptosis through down-regulating human carboxylesterase 1 and -2. Xenobiotica 46 (9):816–824, doi: 10.3109/00498254.2015.1125560 pmid:26750665.
    OpenUrlCrossRefPubMed
  85. ↵
    1. Nowak A,
    2. Zakłos-Szyda M,
    3. Błasiak J,
    4. Nowak A,
    5. Zhang Z, and
    6. Zhang B
    (2019) Potential of Schisandra chinensis (turcz.) Baill. In human health and nutrition: a review of current knowledge and therapeutic perspectives. Nutrients 11:333.
    OpenUrl
  86. ↵
    1. Nunes S,
    2. Danesi F,
    3. Del Rio D, and
    4. Silva P
    (2018) Resveratrol and inflammatory bowel disease: the evidence so far. Nutr Res Rev 31:85–97.
    OpenUrlCrossRefPubMed
  87. ↵
    1. Omar HR,
    2. Komarova I,
    3. El-Ghonemi M,
    4. Fathy A,
    5. Rashad R,
    6. Abdelmalak HD,
    7. Yerramadha MR,
    8. Ali Y,
    9. Helal E, and
    10. Camporesi EM
    (2012) Licorice abuse: time to send a warning message. Ther Adv Endocrinol Metab 3:125–138.
    OpenUrlCrossRefPubMed
  88. ↵
    1. Parker RB,
    2. Hu ZY,
    3. Meibohm B, and
    4. Laizure SC
    (2015) Effects of alcohol on human carboxylesterase drug metabolism. Clin Pharmacokinet 54:627–638.
    OpenUrlCrossRefPubMed
  89. ↵
    1. Pastorino G,
    2. Cornara L,
    3. Soares S,
    4. Rodrigues F, and
    5. Oliveira MBPP
    (2018) Liquorice (Glycyrrhiza glabra): a phytochemical and pharmacological review. Phytother Res 32:2323–2339.
    OpenUrl
  90. ↵
    1. Patlolla JM and
    2. Rao CV
    (2012) Triterpenoids for cancer prevention and treatment: current status and future prospects. Curr Pharm Biotechnol 13:147–155.
    OpenUrlCrossRefPubMed
  91. ↵
    1. Patrician A,
    2. Versic-Bratincevic M,
    3. Mijacika T,
    4. Banic I,
    5. Marendic M,
    6. Sutlović D,
    7. Dujić Ž, and
    8. Ainslie PN
    (2019) Examination of a new delivery approach for oral cannabidiol in healthy subjects: a randomized, double-blinded, placebo-controlled pharmacokinetics study. Adv Ther 36:3196–3210.
    OpenUrl
  92. ↵
    1. Patrick KS,
    2. Straughn AB,
    3. Reeves OT III.,
    4. Bernstein H,
    5. Bell GH,
    6. Anderson ER, and
    7. Malcolm RJ
    (2013) Differential influences of ethanol on early exposure to racemic methylphenidate compared with dexmethylphenidate in humans. Drug Metab Dispos 41:197–205.
    OpenUrlAbstract/FREE Full Text
  93. ↵
    1. Perez-Reyes M,
    2. Di Guiseppi S,
    3. Davis KH,
    4. Schindler VH, and
    5. Cook CE
    (1982) Comparison of effects of marihuana cigarettes to three different potencies. Clin Pharmacol Ther 31:617–624.
    OpenUrlCrossRefPubMed
  94. ↵
    1. Ploeger B,
    2. Mensinga T,
    3. Sips A,
    4. Seinen W,
    5. Meulenbelt J, and
    6. DeJongh J
    (2001) The pharmacokinetics of glycyrrhizic acid evaluated by physiologically based pharmacokinetic modeling. Drug Metab Rev 33:125–147.
    OpenUrlCrossRefPubMed
  95. ↵
    1. Poivre M and
    2. Duez P
    (2017) Biological activity and toxicity of the Chinese herb Magnolia officinalis Rehder & E. Wilson (Houpo) and its constituents. J Zhejiang Univ Sci B 18:194–214.
    OpenUrl
  96. ↵
    1. Qian Y,
    2. Gilliland TK, and
    3. Markowitz JS
    (2020) The influence of carboxylesterase 1 polymorphism and cannabidiol on the hepatic metabolism of heroin. Chem Biol Interact 316:108914.
    OpenUrl
  97. ↵
    1. Qian Y,
    2. Gurley BJ, and
    3. Markowitz JS
    (2019a) The potential for pharmacokinetic interactions between cannabis products and conventional medications. J Clin Psychopharmacol 39:462–471.
    OpenUrl
  98. ↵
    1. Qian Y,
    2. Wang X, and
    3. Markowitz JS
    (2019b) In vitro inhibition of carboxylesterase 1 by major cannabinoids and selected metabolites. Drug Metab Dispos 47:465–472.
    OpenUrlAbstract/FREE Full Text
  99. ↵
    1. Rada M,
    2. Castellano JM,
    3. Perona JS, and
    4. Guinda Á
    (2015) GC-FID determination and pharmacokinetic studies of oleanolic acid in human serum. Biomed Chromatogr 29:1687–1692.
    OpenUrl
  100. ↵
    1. Rebello CJ,
    2. Beyl RA,
    3. Lertora JJL,
    4. Greenway FL,
    5. Ravussin E,
    6. Ribnicky DM,
    7. Poulev A,
    8. Kennedy BJ,
    9. Castro HF,
    10. Campagna SR, et al.
    (2020) Safety and pharmacokinetics of naringenin: a randomized, controlled, single-ascending-dose clinical trial. Diabetes Obes Metab 22:91–98.
    OpenUrl
  101. ↵
    1. Ross MK and
    2. Crow JA
    (2007) Human carboxylesterases and their role in xenobiotic and endobiotic metabolism. J Biochem Mol Toxicol 21:187–196.
    OpenUrlCrossRefPubMed
  102. ↵
    1. Sadakane C,
    2. Watanabe J,
    3. Fukutake M,
    4. Nisimura H,
    5. Maemura K,
    6. Kase Y, and
    7. Kono T
    (2015) Pharmacokinetic profiles of active components after oral administration of a kampo medicine, shakuyakukanzoto, to healthy adult Japanese volunteers. J Pharm Sci 104:3952–3959.
    OpenUrl
  103. ↵
    1. Schwope DM,
    2. Karschner EL,
    3. Gorelick DA, and
    4. Huestis MA
    (2011) Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem 57:1406–1414.
    OpenUrlAbstract/FREE Full Text
  104. ↵
    1. Shergis JL,
    2. Zhang AL,
    3. Zhou W, and
    4. Xue CC
    (2013) Panax ginseng in randomised controlled trials: a systematic review. Phytother Res 27:949–965.
    OpenUrl
  105. ↵
    1. Shimizu M,
    2. Fukami T,
    3. Nakajima M, and
    4. Yokoi T
    (2014) Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase. Drug Metab Dispos 42:1103–1109.
    OpenUrlAbstract/FREE Full Text
  106. ↵
    1. Smith T,
    2. Gillespie M,
    3. Eckl V,
    4. Knepper J, and
    5. Morton-Reynolds C
    (2019) Herbal supplement sales in US increase by 9.4% in 2018. HerbalGram (123):62–73.
  107. ↵
    1. Song M,
    2. Hang TJ,
    3. Wang Y,
    4. Jiang L,
    5. Wu XL,
    6. Zhang Z,
    7. Shen J, and
    8. Zhang Y
    (2006) Determination of oleanolic acid in human plasma and study of its pharmacokinetics in Chinese healthy male volunteers by HPLC tandem mass spectrometry. J Pharm Biomed Anal 40:190–196.
    OpenUrlCrossRefPubMed
  108. ↵
    1. Song PF,
    2. Zhu YD,
    3. Ma HY,
    4. Wang YN,
    5. Wang DD,
    6. Zou LW,
    7. Ge GB, and
    8. Yang L
    (2019a) Discovery of natural pentacyclic triterpenoids as potent and selective inhibitors against human carboxylesterase 1. Fitoterapia 137:104199.
    OpenUrl
  109. ↵
    1. Song YQ,
    2. Weng ZM,
    3. Dou TY,
    4. Finel M,
    5. Wang YQ,
    6. Ding LL,
    7. Jin Q,
    8. Wang DD,
    9. Fang SQ,
    10. Cao YF, et al.
    (2019b) Inhibition of human carboxylesterases by magnolol: kinetic analyses and mechanism. Chem Biol Interact 308:339–349.
    OpenUrl
  110. ↵
    1. Songvut P,
    2. Chariyavilaskul P,
    3. Tantisira MH, and
    4. Khemawoot P
    (2019) Safety and pharmacokinetics of standardized extract of Centella asiatica (ECa 233) capsules in healthy Thai volunteers: a phase 1 clinical study. Planta Med 85:483–490.
    OpenUrl
  111. ↵
    1. Stebounova L,
    2. Ebert SM,
    3. Murry LT,
    4. Adams CM, and
    5. Murry DJ
    (2018) Rapid and sensitive quantification of ursolic acid and oleanolic acid in human plasma using ultra-performance liquid chromatography-mass spectrometry. J Chromatogr Sci 56:644–649.
    OpenUrl
  112. ↵
    1. Su CY,
    2. Ming QL,
    3. Rahman K,
    4. Han T, and
    5. Qin LP
    (2015) Salvia miltiorrhiza: traditional medicinal uses, chemistry, and pharmacology. Chin J Nat Med 13:163–182.
    OpenUrl
  113. ↵
    1. Sun DX,
    2. Ge GB,
    3. Dong PP,
    4. Cao YF,
    5. Fu ZW,
    6. Ran RX,
    7. Wu X,
    8. Zhang YY,
    9. Hua HM,
    10. Zhao Z, et al.
    (2016) Inhibition behavior of fructus psoraleae’s ingredients towards human carboxylesterase 1 (hCES1). Xenobiotica 46:503–510.
    OpenUrl
  114. ↵
    1. Sun ZH,
    2. Chen J,
    3. Song YQ,
    4. Dou TY,
    5. Zou LW,
    6. Hao DC,
    7. Liu HB,
    8. Ge GB, and
    9. Yang L
    (2019) Inhibition of human carboxylesterases by ginsenosides: structure-activity relationships and inhibitory mechanism. Chin Med 14:56.
    OpenUrl
  115. ↵
    1. Suomela JP,
    2. Ahotupa M,
    3. Yang B,
    4. Vasankari T, and
    5. Kallio H
    (2006) Absorption of flavonols derived from sea buckthorn (Hippophaë rhamnoides L.) and their effect on emerging risk factors for cardiovascular disease in humans. J Agric Food Chem 54:7364–7369.
    OpenUrlCrossRefPubMed
  116. ↵
    1. Suzuki T,
    2. Tsukahara M,
    3. Akasaka Y, and
    4. Inoue H
    (2017) A highly sensitive LC-MS/MS method for simultaneous determination of glycyrrhizin and its active metabolite glycyrrhetinic acid: application to a human pharmacokinetic study after oral administration. Biomed Chromatogr 31.
  117. ↵
    1. Tahata S,
    2. Singh SV,
    3. Lin Y,
    4. Hahm ER,
    5. Beumer JH,
    6. Christner SM,
    7. Rao UN,
    8. Sander C,
    9. Tarhini AA,
    10. Tawbi H, et al.
    (2018) Evaluation of biodistribution of sulforaphane after administration of oral broccoli sprout extract in melanoma patients with multiple atypical nevi. Cancer Prev Res (Phila) 11:429–438.
    OpenUrlAbstract/FREE Full Text
  118. ↵
    1. Takeda S,
    2. Ono H,
    3. Wakui Y,
    4. Asami A,
    5. Matsuzaki Y,
    6. Sasaki H,
    7. Aburada M, and
    8. Hosoya E
    (1990) Determination of glycyrrhetic acid in human serum by high-performance liquid chromatography with ultraviolet detection. J Chromatogr A 530:447–451.
    OpenUrl
  119. ↵
    1. Tanaka N,
    2. Yamamura Y,
    3. Santa T,
    4. Kotaki H,
    5. Uchino K,
    6. Sawada Y,
    7. Aikawa T,
    8. Osuga T, and
    9. Iga T
    (1993) Pharmacokinetic profiles of glycyrrhizin in patients with chronic hepatitis. Biopharm Drug Dispos 14:609–614.
    OpenUrlCrossRefPubMed
  120. ↵
    1. Tarkiainen EK,
    2. Backman JT,
    3. Neuvonen M,
    4. Neuvonen PJ,
    5. Schwab M, and
    6. Niemi M
    (2012) Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans. Clin Pharmacol Ther 92:68–71.
    OpenUrlCrossRefPubMed
  121. ↵
    1. Tarkiainen EK,
    2. Holmberg MT,
    3. Tornio A,
    4. Neuvonen M,
    5. Neuvonen PJ,
    6. Backman JT, and
    7. Niemi M
    (2015) Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. Clin Pharmacol Ther 97:650–658.
    OpenUrlCrossRefPubMed
  122. ↵
    1. Taylor L,
    2. Gidal B,
    3. Blakey G,
    4. Tayo B, and
    5. Morrison G
    (2018) A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs 32:1053–1067.
    OpenUrlCrossRefPubMed
  123. ↵
    1. Vallejo F,
    2. Larrosa M,
    3. Escudero E,
    4. Zafrilla MP,
    5. Cerdá B,
    6. Boza J,
    7. García-Conesa MT,
    8. Espín JC, and
    9. Tomás-Barberán FA
    (2010) Concentration and solubility of flavanones in orange beverages affect their bioavailability in humans. J Agric Food Chem 58:6516–6524.
    OpenUrlCrossRefPubMed
  124. ↵
    1. Vanduchova A,
    2. Anzenbacher P, and
    3. Anzenbacherova E
    (2019) Isothiocyanate from broccoli, sulforaphane, and its properties. J Med Food 22:121–126.
    OpenUrl
  125. ↵
    1. Ververidis F,
    2. Trantas E,
    3. Douglas C,
    4. Vollmer G,
    5. Kretzschmar G, and
    6. Panopoulos N
    (2007) Biotechnology of flavonoids and other phenylpropanoid-derived natural products. Part I: chemical diversity, impacts on plant biology and human health. Biotechnol J 2:1214–1234.
    OpenUrlCrossRefPubMed
  126. ↵
    1. Wang D,
    2. Zou L,
    3. Jin Q,
    4. Hou J,
    5. Ge G, and
    6. Yang L
    (2018a) Human carboxylesterases: a comprehensive review. Acta Pharm Sin B 8:699–712.
    OpenUrl
  127. ↵
    1. Wang YQ,
    2. Weng ZM,
    3. Dou TY,
    4. Hou J,
    5. Wang DD,
    6. Ding LL,
    7. Zou LW,
    8. Yu Y,
    9. Chen J,
    10. Tang H, et al.
    (2018b) Nevadensin is a naturally occurring selective inhibitor of human carboxylesterase 1. Int J Biol Macromol 120 (Pt B):1944–1954.
    OpenUrl
  128. ↵
    1. Wiczkowski W,
    2. Romaszko J,
    3. Bucinski A,
    4. Szawara-Nowak D,
    5. Honke J,
    6. Zielinski H, and
    7. Piskula MK
    (2008) Quercetin from shallots (Allium cepa L. var. aggregatum) is more bioavailable than its glucosides. J Nutr 138:885–888.
    OpenUrlAbstract/FREE Full Text
  129. ↵
    1. Wienkers LC and
    2. Heath TG
    (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825–833.
    OpenUrlCrossRefPubMed
  130. ↵
    1. Wittemer SM,
    2. Ploch M,
    3. Windeck T,
    4. Müller SC,
    5. Drewelow B,
    6. Derendorf H, and
    7. Veit M
    (2005) Bioavailability and pharmacokinetics of caffeoylquinic acids and flavonoids after oral administration of Artichoke leaf extracts in humans. Phytomedicine 12:28–38.
    OpenUrlPubMed
  131. ↵
    1. Xing L,
    2. Tan ZR,
    3. Cheng JL,
    4. Huang WH,
    5. Zhang W,
    6. Deng W,
    7. Yuan CS, and
    8. Zhou HH
    (2017) Bioavailability and pharmacokinetic comparison of tanshinones between two formulations of Salvia miltiorrhiza in healthy volunteers. Sci Rep 7:4709.
    OpenUrl
  132. ↵
    1. Xiong X,
    2. Jiang J,
    3. Duan J,
    4. Xie Y,
    5. Wang J, and
    6. Zhai S
    (2014) Development and validation of a sensitive liquid chromatography-tandem mass spectrometry method for the determination of naringin and its metabolite, naringenin, in human plasma. J Chromatogr Sci 52:654–660.
    OpenUrlCrossRefPubMed
  133. ↵
    1. Yang D,
    2. Yang J,
    3. Shi D,
    4. Xiao D,
    5. Chen YT,
    6. Black C,
    7. Deng R, and
    8. Yan B
    (2012) Hypolipidemic agent Z-guggulsterone: metabolism interplays with induction of carboxylesterase and bile salt export pump. J Lipid Res 53:529–539.
    OpenUrlAbstract/FREE Full Text
  134. ↵
    1. Zhang L,
    2. Zhang YD,
    3. Zhao P, and
    4. Huang SM
    (2009) Predicting drug-drug interactions: an FDA perspective. AAPS J 11:300–306.
    OpenUrlCrossRefPubMed
  135. ↵
    1. Zhang Y,
    2. Lyu C,
    3. Fong SYK,
    4. Wang Q,
    5. Li C,
    6. Ho NJ,
    7. Chan KS,
    8. Yan X, and
    9. Zuo Z
    (2019) Evaluation of potential herb-drug interactions between oseltamivir and commonly used anti-influenza Chinese medicinal herbs. J Ethnopharmacol 243:112097.
    OpenUrl
  136. ↵
    1. Zhao WJ,
    2. Wang BJ,
    3. Wei CM,
    4. Yuan GY,
    5. Bu FL, and
    6. Guo RC
    (2008) Determination of glycyrrhetic acid in human plasma by HPLC-MS method and investigation of its pharmacokinetics. J Clin Pharm Ther 33:289–294.
    OpenUrlPubMed
  137. ↵
    1. Zhou CH,
    2. Xu M,
    3. Yu HB,
    4. Zheng XT,
    5. Zhong ZF, and
    6. Zhang LT
    (2018) Effects of Danshen capsules on the pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. Food Chem Toxicol 119:302–308.
    OpenUrl
  138. ↵
    1. Zhou Qi-Hang,
    2. Zhu Ya-Di,
    3. Zhang Feng,
    4. Song Yun-Qing,
    5. Jia Shou-Ning,
    6. Zhu Liang,
    7. Fang Sheng-Quan, and
    8. Ge Guang-Bo
    (2019) Interactions of drug-metabolizing enzymes with the Chinese herb Psoraleae Fructus. Chin J Nat Med 17 (11):858–870, doi: 10.1016/S1875-5364(19)30103-7 pmid:31831132.
    OpenUrlCrossRefPubMed
  139. ↵
    1. Zhu HJ and
    2. Markowitz JS
    (2009) Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Drug Metab Dispos 37:264–267.
    OpenUrlAbstract/FREE Full Text
  140. ↵
    1. Zhu HJ,
    2. Patrick KS, and
    3. Markowitz JS
    (2011) Enantiospecific determination of DL-methylphenidate and DL-ethylphenidate in plasma by liquid chromatography-tandem mass spectrometry: application to human ethanol interactions. J Chromatogr B Analyt Technol Biomed Life Sci 879:783–788.
    OpenUrlCrossRefPubMed
  141. ↵
    1. Zhu HJ,
    2. Patrick KS,
    3. Straughn AB,
    4. Reeves OT III.,
    5. Bernstein H,
    6. Shi J,
    7. Johnson HJ,
    8. Knight JM,
    9. Smith AT,
    10. Malcolm RJ, et al.
    (2017) Ethanol interactions with dexmethylphenidate and dl-methylphenidate spheroidal oral drug absorption systems in healthy volunteers. J Clin Psychopharmacol 37:419–428.
    OpenUrl
  142. ↵
    1. Zhu HJ,
    2. Patrick KS,
    3. Yuan HJ,
    4. Wang JS,
    5. Donovan JL,
    6. DeVane CL,
    7. Malcolm R,
    8. Johnson JA,
    9. Youngblood GL,
    10. Sweet DH, et al.
    (2008) Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet 82:1241–1248.
    OpenUrlCrossRefPubMed
  143. ↵
    1. Zhu Z,
    2. Qian Z,
    3. Yan Z,
    4. Zhao C,
    5. Wang H, and
    6. Ying G
    (2013) A phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors. Int J Nanomedicine 8:129–136.
    OpenUrlPubMed
  144. ↵
    1. Zou J,
    2. Lin J,
    3. Li C,
    4. Zhao R,
    5. Fan L,
    6. Yu J, and
    7. Shao J
    (2019) Ursolic acid in cancer treatment and metastatic chemoprevention: from synthesized derivatives to nanoformulations in preclinical studies. Curr Cancer Drug Targets 19:245–256.
    OpenUrl
  145. ↵
    1. Zou LW,
    2. Dou TY,
    3. Wang P,
    4. Lei W,
    5. Weng ZM,
    6. Hou J,
    7. Wang DD,
    8. Fan YM,
    9. Zhang WD,
    10. Ge GB, et al.
    (2017) Structure-activity relationships of pentacyclic triterpenoids as potent and selective inhibitors against human carboxylesterase 1. Front Pharmacol 8:435.
    OpenUrl
  146. ↵
    1. Zou Q,
    2. Wei P,
    3. Li J,
    4. Ge ZX, and
    5. Ouyang P
    (2009) Simultaneous determination of 18alpha- and 18beta-glycyrrhetic acid in human plasma by LC-ESI-MS and its application to pharmacokinetics. Biomed Chromatogr 23:54–62.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 48 (10)
Drug Metabolism and Disposition
Vol. 48, Issue 10
1 Oct 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Natural Products as Modulators of CES1 Activity
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleSpecial Section on Natural Products: Experimental Approaches to Elucidate Disposition Mechanisms and Predict Pharmacokinetic Drug Interactions — Minireview

CES1 and Natural Products

Yuli Qian and John S. Markowitz
Drug Metabolism and Disposition October 1, 2020, 48 (10) 993-1007; DOI: https://doi.org/10.1124/dmd.120.000065

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleSpecial Section on Natural Products: Experimental Approaches to Elucidate Disposition Mechanisms and Predict Pharmacokinetic Drug Interactions — Minireview

CES1 and Natural Products

Yuli Qian and John S. Markowitz
Drug Metabolism and Disposition October 1, 2020, 48 (10) 993-1007; DOI: https://doi.org/10.1124/dmd.120.000065
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • TCM Natural Products as P-gp–Mediated MDR Reversal Agents
  • In Vitro Human Cell–Based Enteric Experimental Models
Show more Special Section on Natural Products: Experimental Approaches to Elucidate Disposition Mechanisms and Predict Pharmacokinetic Drug Interactions — Minireview

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics